Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Atossa Genetics Inc(ATOS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ATOS
09/28/2026: ATOS (1-star) is currently NOT-A-BUY. Pass it for now.
Atossa Genetics Inc, operating as Atossa Therapeutics, is a clinical-stage biopharmaceutical firm focused on developing proprietary treatments for breast cancer, specifically its lead candidate (Z)-endoxifen. The company's strengths lie in its specialized oncology pipeline and intellectual property, though it currently lacks commercial product revenue and remains highly dependent on clinical success. The primary growth opportunity involves the potential to disrupt standard endocrine therapies. Significant risks include high volatility, the possibility of clinical failure, and intense competition from large pharmaceutical companies. The stock is best suited for risk-tolerant investors looking for long-term speculative exposure to the oncology sector, with key developments in clinical trials to monitor.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The growth potential is high if clinical trials succeed, but the speculative nature of the pipeline carries significant risk. |
| Momentum investor | Strong fit while signal remains positive | The stock often experiences high volatility and speculative trading volume, which can favor momentum strategies during positive news cycles. |
| Value investor | Weak fit | Valuation is difficult to derive due to the lack of revenue or consistent profitability. |
| Dividend investor | Weak fit | The company does not pay a dividend and has no near-term path to cash distributions. |
| Low-risk investor | Weak fit | High volatility and binary clinical trial outcomes make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant price swings driven by clinical trial news and biotech sector sentiment. |
| Valuation risk | High | As a clinical-stage firm, current valuations are based on subjective future projections rather than current fundamentals. |
| Competition risk (Biopharma giants) | High | Larger companies with more resources can outspend and outcompete Atossa in clinical development and commercialization. |
| Business quality | Medium | The company has a focused niche strategy, but lacks the commercial scale of established competitors. |
| Dividend income | Low / none | There is no income generation for investors from this security. |
| Execution risk | High | Success depends entirely on the ability to navigate complex clinical trials and achieve regulatory approvals. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 14.58% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.96M USD | Price to earnings Ratio - | 1Y Target Price 18.67 |
Price to earnings Ratio - | 1Y Target Price 18.67 | ||
Volume (30-day avg) 58.8K shares | Beta 1.27 | 52 Weeks Range 1.70 - 19.35 | Updated Date 09/27/2026 |
52 Weeks Range 1.70 - 19.35 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.34 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Research / Therapeutics | Potential licensing and milestone payments from drug candidates like (Z)-endoxifen. | Atossa currently earns no money; investors are betting on the future success and potential buyout or licensing of their drug candidates. |
Valuation
Trailing PE - | Forward PE 7.04 | Enterprise Value -4.24M | Price to Sales(TTM) 1872.06 |
Enterprise Value -4.24M | Price to Sales(TTM) 1872.06 | ||
Enterprise Value to Revenue 3287.25 | Enterprise Value to EBITDA 2.01 | Shares Outstanding 9.98M | Shares Floating 9.94M |
Shares Outstanding 9.98M | Shares Floating 9.94M | ||
Percent Insiders 1.85 | Percent Institutions 17.39 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Atossa Genetics Inc
Exchange NASDAQ | Headquarters Seattle, WA, United States | ||
IPO Launch date 2012-11-08 | Chairman, CEO & President Dr. Steven C. Quay FCAP, M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | |
Full time employees 16 | |||
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.